Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response

Chiara Fabbri, Ladislav Hosak, Rainald Mössner, Ina Giegling, Laura Mandelli, Frank Bellivier, Stephan Claes, David A. Collier, Alejo Corrales, Lynn E. Delisi, Carla Gallo, Michael Gill, James L. Kennedy, Marion Leboyer, Amanda Lisoway, Wolfgang Maier, Miguel Marquez, Isabelle Massat, Ole Mors, Pierandrea Muglia & 11 others Markus M. Nöthen, Michael C. O’Donovan, Jorge Ospina-Duque, Peter Propping, Yongyong Shi, David St Clair, Florence Thibaut, Sven Cichon, Julien Mendlewicz, Dan Rujescu, Alessandro Serretti

Research output: Contribution to journalReview article

28 Citations (Scopus)

Abstract

Major depressive disorder (MDD) is a heritable disease with a heavy personal and socio-economic burden. Antidepressants of different classes are prescribed to treat MDD, but reliable and reproducible markers of efficacy are not available for clinical use. Further complicating treatment, the diagnosis of MDD is not guided by objective criteria, resulting in the risk of under- or overtreatment. A number of markers of MDD and antidepressant response have been investigated at the genetic, epigenetic, gene expression and protein levels. Polymorphisms in genes involved in antidepressant metabolism (cytochrome P450 isoenzymes), antidepressant transport (ABCB1), glucocorticoid signalling (FKBP5) and serotonin neurotransmission (SLC6A4 and HTR2A) were among those included in the first pharmacogenetic assays that have been tested for clinical applicability. The results of these investigations were encouraging when examining patient-outcome improvement. Furthermore, a nine-serum biomarker panel (including BDNF, cortisol and soluble TNF-α receptor type II) showed good sensitivity and specificity in differentiating between MDD and healthy controls. These first diagnostic and response-predictive tests for MDD provided a source of optimism for future clinical applications. However, such findings should be considered very carefully because their benefit/cost ratio and clinical indications were not clearly demonstrated. Future tests may include combinations of different types of biomarkers and be specific for MDD subtypes or pathological dimensions.

Original languageEnglish
Pages (from-to)5-28
Number of pages24
JournalWorld Journal of Biological Psychiatry
Volume18
Issue number1
Early online date7 Sep 2016
DOIs
Publication statusPublished - 2017

Fingerprint

Major Depressive Disorder
Advisory Committees
Epigenomics
Antidepressive Agents
Consensus
Gene Expression
Biomarkers
Tumor Necrosis Factor Receptors
Pharmacogenetics
Brain-Derived Neurotrophic Factor
Synaptic Transmission
Cytochrome P-450 Enzyme System
Glucocorticoids
Isoenzymes
Cost-Benefit Analysis
Hydrocortisone
Serotonin
Economics
Sensitivity and Specificity
Serum

Keywords

  • antidepressant
  • genetics-epigenetics
  • Major depression
  • transcriptomics-proteomics

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Consensus paper of the WFSBP Task Force on Genetics : Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response. / Fabbri, Chiara; Hosak, Ladislav; Mössner, Rainald; Giegling, Ina; Mandelli, Laura; Bellivier, Frank; Claes, Stephan; Collier, David A.; Corrales, Alejo; Delisi, Lynn E.; Gallo, Carla; Gill, Michael; Kennedy, James L.; Leboyer, Marion; Lisoway, Amanda; Maier, Wolfgang; Marquez, Miguel; Massat, Isabelle; Mors, Ole; Muglia, Pierandrea; Nöthen, Markus M.; O’Donovan, Michael C.; Ospina-Duque, Jorge; Propping, Peter; Shi, Yongyong; St Clair, David; Thibaut, Florence; Cichon, Sven; Mendlewicz, Julien; Rujescu, Dan; Serretti, Alessandro.

In: World Journal of Biological Psychiatry, Vol. 18, No. 1, 2017, p. 5-28.

Research output: Contribution to journalReview article

Fabbri, C, Hosak, L, Mössner, R, Giegling, I, Mandelli, L, Bellivier, F, Claes, S, Collier, DA, Corrales, A, Delisi, LE, Gallo, C, Gill, M, Kennedy, JL, Leboyer, M, Lisoway, A, Maier, W, Marquez, M, Massat, I, Mors, O, Muglia, P, Nöthen, MM, O’Donovan, MC, Ospina-Duque, J, Propping, P, Shi, Y, St Clair, D, Thibaut, F, Cichon, S, Mendlewicz, J, Rujescu, D & Serretti, A 2017, 'Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response' World Journal of Biological Psychiatry, vol. 18, no. 1, pp. 5-28. https://doi.org/10.1080/15622975.2016.1208843
Fabbri, Chiara ; Hosak, Ladislav ; Mössner, Rainald ; Giegling, Ina ; Mandelli, Laura ; Bellivier, Frank ; Claes, Stephan ; Collier, David A. ; Corrales, Alejo ; Delisi, Lynn E. ; Gallo, Carla ; Gill, Michael ; Kennedy, James L. ; Leboyer, Marion ; Lisoway, Amanda ; Maier, Wolfgang ; Marquez, Miguel ; Massat, Isabelle ; Mors, Ole ; Muglia, Pierandrea ; Nöthen, Markus M. ; O’Donovan, Michael C. ; Ospina-Duque, Jorge ; Propping, Peter ; Shi, Yongyong ; St Clair, David ; Thibaut, Florence ; Cichon, Sven ; Mendlewicz, Julien ; Rujescu, Dan ; Serretti, Alessandro. / Consensus paper of the WFSBP Task Force on Genetics : Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response. In: World Journal of Biological Psychiatry. 2017 ; Vol. 18, No. 1. pp. 5-28.
@article{0080678d8abe4b2984f3e95b50ecb894,
title = "Consensus paper of the WFSBP Task Force on Genetics: Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response",
abstract = "Major depressive disorder (MDD) is a heritable disease with a heavy personal and socio-economic burden. Antidepressants of different classes are prescribed to treat MDD, but reliable and reproducible markers of efficacy are not available for clinical use. Further complicating treatment, the diagnosis of MDD is not guided by objective criteria, resulting in the risk of under- or overtreatment. A number of markers of MDD and antidepressant response have been investigated at the genetic, epigenetic, gene expression and protein levels. Polymorphisms in genes involved in antidepressant metabolism (cytochrome P450 isoenzymes), antidepressant transport (ABCB1), glucocorticoid signalling (FKBP5) and serotonin neurotransmission (SLC6A4 and HTR2A) were among those included in the first pharmacogenetic assays that have been tested for clinical applicability. The results of these investigations were encouraging when examining patient-outcome improvement. Furthermore, a nine-serum biomarker panel (including BDNF, cortisol and soluble TNF-α receptor type II) showed good sensitivity and specificity in differentiating between MDD and healthy controls. These first diagnostic and response-predictive tests for MDD provided a source of optimism for future clinical applications. However, such findings should be considered very carefully because their benefit/cost ratio and clinical indications were not clearly demonstrated. Future tests may include combinations of different types of biomarkers and be specific for MDD subtypes or pathological dimensions.",
keywords = "antidepressant, genetics-epigenetics, Major depression, transcriptomics-proteomics",
author = "Chiara Fabbri and Ladislav Hosak and Rainald M{\"o}ssner and Ina Giegling and Laura Mandelli and Frank Bellivier and Stephan Claes and Collier, {David A.} and Alejo Corrales and Delisi, {Lynn E.} and Carla Gallo and Michael Gill and Kennedy, {James L.} and Marion Leboyer and Amanda Lisoway and Wolfgang Maier and Miguel Marquez and Isabelle Massat and Ole Mors and Pierandrea Muglia and N{\"o}then, {Markus M.} and O’Donovan, {Michael C.} and Jorge Ospina-Duque and Peter Propping and Yongyong Shi and {St Clair}, David and Florence Thibaut and Sven Cichon and Julien Mendlewicz and Dan Rujescu and Alessandro Serretti",
year = "2017",
doi = "10.1080/15622975.2016.1208843",
language = "English",
volume = "18",
pages = "5--28",
journal = "World Journal of Biological Psychiatry",
issn = "1562-2975",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Consensus paper of the WFSBP Task Force on Genetics

T2 - Genetics, epigenetics and gene expression markers of major depressive disorder and antidepressant response

AU - Fabbri, Chiara

AU - Hosak, Ladislav

AU - Mössner, Rainald

AU - Giegling, Ina

AU - Mandelli, Laura

AU - Bellivier, Frank

AU - Claes, Stephan

AU - Collier, David A.

AU - Corrales, Alejo

AU - Delisi, Lynn E.

AU - Gallo, Carla

AU - Gill, Michael

AU - Kennedy, James L.

AU - Leboyer, Marion

AU - Lisoway, Amanda

AU - Maier, Wolfgang

AU - Marquez, Miguel

AU - Massat, Isabelle

AU - Mors, Ole

AU - Muglia, Pierandrea

AU - Nöthen, Markus M.

AU - O’Donovan, Michael C.

AU - Ospina-Duque, Jorge

AU - Propping, Peter

AU - Shi, Yongyong

AU - St Clair, David

AU - Thibaut, Florence

AU - Cichon, Sven

AU - Mendlewicz, Julien

AU - Rujescu, Dan

AU - Serretti, Alessandro

PY - 2017

Y1 - 2017

N2 - Major depressive disorder (MDD) is a heritable disease with a heavy personal and socio-economic burden. Antidepressants of different classes are prescribed to treat MDD, but reliable and reproducible markers of efficacy are not available for clinical use. Further complicating treatment, the diagnosis of MDD is not guided by objective criteria, resulting in the risk of under- or overtreatment. A number of markers of MDD and antidepressant response have been investigated at the genetic, epigenetic, gene expression and protein levels. Polymorphisms in genes involved in antidepressant metabolism (cytochrome P450 isoenzymes), antidepressant transport (ABCB1), glucocorticoid signalling (FKBP5) and serotonin neurotransmission (SLC6A4 and HTR2A) were among those included in the first pharmacogenetic assays that have been tested for clinical applicability. The results of these investigations were encouraging when examining patient-outcome improvement. Furthermore, a nine-serum biomarker panel (including BDNF, cortisol and soluble TNF-α receptor type II) showed good sensitivity and specificity in differentiating between MDD and healthy controls. These first diagnostic and response-predictive tests for MDD provided a source of optimism for future clinical applications. However, such findings should be considered very carefully because their benefit/cost ratio and clinical indications were not clearly demonstrated. Future tests may include combinations of different types of biomarkers and be specific for MDD subtypes or pathological dimensions.

AB - Major depressive disorder (MDD) is a heritable disease with a heavy personal and socio-economic burden. Antidepressants of different classes are prescribed to treat MDD, but reliable and reproducible markers of efficacy are not available for clinical use. Further complicating treatment, the diagnosis of MDD is not guided by objective criteria, resulting in the risk of under- or overtreatment. A number of markers of MDD and antidepressant response have been investigated at the genetic, epigenetic, gene expression and protein levels. Polymorphisms in genes involved in antidepressant metabolism (cytochrome P450 isoenzymes), antidepressant transport (ABCB1), glucocorticoid signalling (FKBP5) and serotonin neurotransmission (SLC6A4 and HTR2A) were among those included in the first pharmacogenetic assays that have been tested for clinical applicability. The results of these investigations were encouraging when examining patient-outcome improvement. Furthermore, a nine-serum biomarker panel (including BDNF, cortisol and soluble TNF-α receptor type II) showed good sensitivity and specificity in differentiating between MDD and healthy controls. These first diagnostic and response-predictive tests for MDD provided a source of optimism for future clinical applications. However, such findings should be considered very carefully because their benefit/cost ratio and clinical indications were not clearly demonstrated. Future tests may include combinations of different types of biomarkers and be specific for MDD subtypes or pathological dimensions.

KW - antidepressant

KW - genetics-epigenetics

KW - Major depression

KW - transcriptomics-proteomics

UR - http://www.scopus.com/inward/record.url?scp=84986183057&partnerID=8YFLogxK

U2 - 10.1080/15622975.2016.1208843

DO - 10.1080/15622975.2016.1208843

M3 - Review article

VL - 18

SP - 5

EP - 28

JO - World Journal of Biological Psychiatry

JF - World Journal of Biological Psychiatry

SN - 1562-2975

IS - 1

ER -